- Home
- BPOP vs NUVL Comparison
BPOP vs NUVL Comparison
Compare BPOP & NUVL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BPOP
- NUVL
- Stock Information
- Founded
- BPOP 1893
- NUVL 2017
- Country
- BPOP United States
- NUVL United States
- Employees
- BPOP N/A
- NUVL N/A
- Industry
- BPOP Major Banks
- NUVL Biotechnology: Pharmaceutical Preparations
- Sector
- BPOP Finance
- NUVL Health Care
- Exchange
- BPOP Nasdaq
- NUVL Nasdaq
- Market Cap
- BPOP 5.9B
- NUVL 5.6B
- IPO Year
- BPOP N/A
- NUVL 2021
- Fundamental
- Price
- BPOP $100.49
- NUVL $71.60
- Analyst Decision
- BPOP Buy
- NUVL Strong Buy
- Analyst Count
- BPOP 6
- NUVL 8
- Target Price
- BPOP $110.67
- NUVL $115.50
- AVG Volume (30 Days)
- BPOP 626.6K
- NUVL 660.5K
- Earning Date
- BPOP 04-23-2025
- NUVL 05-08-2025
- Dividend Yield
- BPOP 2.79%
- NUVL N/A
- EPS Growth
- BPOP 43.88
- NUVL N/A
- EPS
- BPOP 9.68
- NUVL N/A
- Revenue
- BPOP $2,735,868,000.00
- NUVL N/A
- Revenue This Year
- BPOP N/A
- NUVL N/A
- Revenue Next Year
- BPOP $6.55
- NUVL N/A
- P/E Ratio
- BPOP $10.38
- NUVL N/A
- Revenue Growth
- BPOP 6.94
- NUVL N/A
- 52 Week Low
- BPOP $78.23
- NUVL $55.54
- 52 Week High
- BPOP $106.81
- NUVL $113.51
- Technical
- Relative Strength Index (RSI)
- BPOP 68.70
- NUVL 49.06
- Support Level
- BPOP $97.08
- NUVL $71.60
- Resistance Level
- BPOP $100.53
- NUVL $78.97
- Average True Range (ATR)
- BPOP 2.55
- NUVL 3.41
- MACD
- BPOP 1.00
- NUVL -0.28
- Stochastic Oscillator
- BPOP 93.71
- NUVL 52.19
About BPOP Popular Inc.
Popular Inc, based in Puerto Rico, is a financial holding company with four main subsidiaries: Banco Popular de Puerto Rico, a bank in Puerto Rico in terms of assets; Banco Popular North America, its banking operation in the continental United States; Evertec, a data processor; and Popular Financial Holdings, a diversified financial services company. The Corporation's reportable segments consist of Banco Popular de Puerto Rico and Popular U.S.
About NUVL Nuvalent Inc.
Nuvalent Inc is a clinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. All of the Company's operations are in the United States. The company is engaged in developing small molecules that are designed to overcome the limitations of existing therapies for clinically proven kinase targets. The product candidates of the company include NVL-520, which is being developed for patients with ROS1-positive non-small cell lung cancer (NSCLC), NVL-655, which is being developed for patients with anaplastic lymphoma kinase (ALK)-positive NSCLC, NVL-330, is a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to address the combined medical need of treating tumors driven by HER2ex20.